EP3884947
Aukning á aðgengi lyfs í naltrexón-meðferð
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.12.2011EP published:
15.11.2023EP application number:
21152314.7
EP translation filed:
1.2.2024Grant published:
15.3.2024EPO information:
European Patent Register
Max expiry date:
1.12.2031Expiry date:
1.12.2026Next due date:
31.12.2026
Title in English:
INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPYLanguage of the patent:
English
Timeline
Today
2.12.2011EP application
15.11.2023EP Publication
1.2.2024Translation submitted
15.3.2024Registration published
1.12.2026Expires
Owner
Name:
Nalpropion Pharmaceuticals LLCAddress:
155 Franklin Rd, Suite 450, Brentwood, TN 37027, US
Inventor
Name:
FLANAGAN,, ShawnAddress:
San Diego,, CA California 92128, US
Name:
DUNAYEVICH,, EduardoAddress:
Westlake Village,, CA California 91362, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
41939510 PDate:
3.12.2010Country:
US
Classification
Categories:
A61K 31/485, A61K 31/137, A61P 3/04, A61K 45/06
Annual fees
Number
Paid
Expires
Payer
Number: 13
Paid: 1.2.2024
Expires: 1.12.2024
Payer: Árnason Faktor ehf.
Number: 14
Paid: 28.11.2024
Expires: 1.12.2025
Payer: Árnason Faktor ehf.
Number: 15
Paid: 5.12.2025
Expires: 1.12.2026
Payer: Árnason Faktor ehf.